LUC00126I2 - - Google Patents
Download PDFInfo
- Publication number
- LUC00126I2 LUC00126I2 LU00126C LUC00126C LUC00126I2 LU C00126 I2 LUC00126 I2 LU C00126I2 LU 00126 C LU00126 C LU 00126C LU C00126 C LUC00126 C LU C00126C LU C00126 I2 LUC00126 I2 LU C00126I2
- Authority
- LU
- Luxembourg
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73662305P | 2005-11-14 | 2005-11-14 | |
EP06809207.1A EP1957106B2 (fr) | 2005-11-14 | 2006-11-02 | Anticorps antagonistes orientes contre un peptide lie au gene de la calcitonine, et procedes d'utilisation correspondants |
Publications (2)
Publication Number | Publication Date |
---|---|
LUC00126I1 LUC00126I1 (fr) | 2019-07-09 |
LUC00126I2 true LUC00126I2 (fr) | 2019-12-27 |
Family
ID=37909474
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU00119C LUC00119I2 (fr) | 2005-11-14 | 2019-05-08 | |
LU00126C LUC00126I2 (fr) | 2005-11-14 | 2019-07-04 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU00119C LUC00119I2 (fr) | 2005-11-14 | 2019-05-08 |
Country Status (38)
Country | Link |
---|---|
US (19) | US8007794B2 (fr) |
EP (6) | EP1957106B2 (fr) |
JP (1) | JP5123197B2 (fr) |
KR (2) | KR20080068062A (fr) |
CN (2) | CN101309704B (fr) |
AP (1) | AP2008004467A0 (fr) |
AU (1) | AU2006313434B2 (fr) |
BR (1) | BRPI0618705B8 (fr) |
CA (1) | CA2626120C (fr) |
CR (1) | CR9975A (fr) |
CU (1) | CU23872B1 (fr) |
CY (3) | CY1120249T1 (fr) |
DK (3) | DK2380592T3 (fr) |
EA (1) | EA015526B1 (fr) |
EC (1) | ECSP088451A (fr) |
ES (3) | ES2664854T3 (fr) |
GE (1) | GEP20115333B (fr) |
HK (2) | HK1125837A1 (fr) |
HR (2) | HRP20180752T1 (fr) |
HU (3) | HUE036940T2 (fr) |
IL (3) | IL190876A (fr) |
LT (3) | LT2380592T (fr) |
LU (2) | LUC00119I2 (fr) |
MA (1) | MA30136B1 (fr) |
ME (1) | ME00419B (fr) |
MY (1) | MY153249A (fr) |
NL (1) | NL300997I2 (fr) |
NO (3) | NO344099B1 (fr) |
NZ (1) | NZ568237A (fr) |
PL (3) | PL3045182T3 (fr) |
PT (3) | PT1957106E (fr) |
RS (3) | RS57192B1 (fr) |
SI (3) | SI2380592T1 (fr) |
SV (1) | SV2008002905A (fr) |
TN (1) | TNSN08213A1 (fr) |
UA (1) | UA94244C2 (fr) |
WO (1) | WO2007054809A2 (fr) |
ZA (1) | ZA200803484B (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME00419B (fr) | 2005-11-14 | 2011-10-10 | Rinat Neuroscience Corp | Anticorps antagonistes orientes contre un peptide lie au gene de la calcitonine, et procedes d'utilisation correspondants |
PL2265288T3 (pl) * | 2008-03-04 | 2017-01-31 | Labrys Biologics Inc | Sposoby leczenia bólu zapalnego |
AU2009220900B2 (en) * | 2008-03-04 | 2014-09-11 | Teva Pharmaceuticals International Gmbh | Methods of treating chronic pain |
DK2278880T3 (da) | 2008-04-09 | 2012-11-12 | Pherin Pharm Inc | Steroidbehandling af hedeture |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
WO2010107695A1 (fr) | 2009-03-16 | 2010-09-23 | Colder Products Company | Dispositifs pour accouplement aseptique |
IN2012DN02521A (fr) * | 2009-08-28 | 2015-08-28 | Rinat Neuroscience Corp | |
AR081434A1 (es) * | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
CN107566845B (zh) | 2011-02-10 | 2020-03-03 | 威勒斯媒体国际有限公司 | 图像处理设备和图像处理方法 |
PT2710039T (pt) * | 2011-05-20 | 2019-04-23 | Alderbio Holdings Llc | Composições anti-cgrp e a sua utilização |
CA2836799C (fr) * | 2011-05-20 | 2021-05-18 | Alderbio Holdings Llc | Utilisation d'anticorps ou de fragments d'anticorps anti-cgrp ou anti-cgrp-r dans le traitement ou la prevention de formes chroniques et aigues de la diarrhee |
NZ732970A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
EP2807187B1 (fr) * | 2012-01-26 | 2017-07-26 | Christopher J. Soares | Antagonistes peptidiques de la famille calcitonine cgrp d'hormones peptidiques et leur utilisation |
EP3024532B1 (fr) | 2013-07-23 | 2019-01-02 | Colder Products Company | Connecteurs aseptiques |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
FI3119431T3 (fi) * | 2014-03-21 | 2024-03-20 | Teva Pharmaceuticals Int Gmbh | Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi |
EP3142699A4 (fr) * | 2014-05-16 | 2017-11-22 | Salk Institute for Biological Studies | Compositions et méthodes pour le traitement de troubles métaboliques |
WO2016028608A1 (fr) | 2014-08-17 | 2016-02-25 | Nine Continents Medical, Inc. | Système de neurostimulateur implantable miniature pour le nerf sciatique et ses ramifications |
US10934362B2 (en) | 2014-09-15 | 2021-03-02 | Amgen Inc. | Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof |
JO3669B1 (ar) * | 2015-01-06 | 2020-08-27 | Ferring Bv | بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين |
JOP20200116A1 (ar) * | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
AR104847A1 (es) | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
WO2017051385A1 (fr) * | 2015-09-24 | 2017-03-30 | Teva Pharmaceuticals International Gmbh | Prévention, traitement, et diminution (persistance) d'une céphalée post-traumatique |
KR20180091930A (ko) * | 2016-01-28 | 2018-08-16 | 일라이 릴리 앤드 캄파니 | Cgrp 항체 및 그의 용도 |
CN108601833B (zh) | 2016-02-01 | 2022-11-15 | 伊莱利利公司 | 甲状旁腺激素-抗rankl抗体融合化合物 |
JP7116685B2 (ja) | 2016-04-15 | 2022-08-10 | エイチ. ルンドベック アー/エス | ヒト化抗pacap抗体及びそれらの使用 |
EP3487868A4 (fr) * | 2016-07-25 | 2020-07-29 | Cephalon, Inc. | Tampon de lavage pour chromatographie par affinité |
JP7123932B2 (ja) | 2016-09-02 | 2022-08-23 | クリストファー ジェイ. ソアレス | 神経保護及び神経疾患におけるcgrp受容体アンタゴニストの使用 |
EP3515488A1 (fr) * | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Traitement de l'algie vasculaire de la face |
PE20191148A1 (es) * | 2016-09-23 | 2019-09-02 | Teva Pharmaceuticals Int Gmbh | Tratamiento de la migrana refractaria |
CN106442967B (zh) * | 2016-09-27 | 2018-05-15 | 鸿运华宁(杭州)生物医药有限公司 | 一种检测跨膜蛋白单克隆抗体亲和力的方法 |
GB2557655A (en) | 2016-12-14 | 2018-06-27 | Teva Pharma | Medical injection device packaging |
MX2019010397A (es) * | 2017-03-02 | 2020-08-20 | Beth Israel Deaconess Medical Ct Inc | Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina. |
EP3641746A4 (fr) * | 2017-06-19 | 2021-03-17 | President And Fellows Of Harvard College | Méthodes et compositions pour le traitement d'une infection microbienne |
WO2018237159A1 (fr) | 2017-06-21 | 2018-12-27 | Cephalon, Inc. | Tampon de lavage pour chromatographie d'échange cationique |
MX2020006976A (es) | 2018-01-12 | 2020-10-05 | Amgen Inc | Anticuerpos del receptor de tipo i del polipeptido activador de la adenilato?ciclasa hipofisaria (pac1) y sus usos. |
WO2019165326A1 (fr) * | 2018-02-23 | 2019-08-29 | REMD Biotherapeutics, Inc | Anticorps antagonistes du peptide lié au gène de la calcitonine (cgrp) |
US11295402B2 (en) | 2018-03-28 | 2022-04-05 | Bank Of America Corporation | Blockchain-based property repair |
US11475422B2 (en) | 2018-03-28 | 2022-10-18 | Bank Of America Corporation | Blockchain-based property management |
US10498808B2 (en) | 2018-03-28 | 2019-12-03 | Bank Of America Corporation | Blockchain-based property management |
SG11202009629YA (en) | 2018-04-02 | 2020-10-29 | Amgen Inc | Erenumab compositions and uses thereof |
US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
WO2020058764A2 (fr) | 2018-09-20 | 2020-03-26 | Teva Pharmaceuticals International Gmbh | Ressort d'injection pour seringue pré-remplie vieillie et auto-injecteur |
CN113574073A (zh) * | 2018-12-31 | 2021-10-29 | 联脑科学有限公司 | 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂 |
CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
US11781687B2 (en) | 2019-08-27 | 2023-10-10 | Colder Products Company | Single-use genderless aseptic fluid couplings |
CA3153776A1 (fr) * | 2019-09-09 | 2021-03-18 | The University Of Chicago | Polytherapie pour le traitement de migraines |
CN112274302B (zh) * | 2020-11-24 | 2021-07-13 | 四川大学华西医院 | 一种多单元可调的智能化椎间融合器 |
IT202000029459A1 (it) * | 2020-12-03 | 2022-06-03 | Alberto Chiarugi | Terapia dei disturbi emotivi |
KR20230157986A (ko) | 2021-03-02 | 2023-11-17 | 체게에르페 다이어그노스틱스 게엠베하 | 편투통 발생의 치료 및/또는 저감 |
WO2023026205A1 (fr) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Traitement préventif de la migraine |
WO2023139542A1 (fr) * | 2022-01-21 | 2023-07-27 | Institut Pasteur De Montevideo | Immunisation active pour réduire la douleur arthrosique, neuropathique et cancéreuse |
WO2023161528A1 (fr) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | Conjugué comprenant au moins un ss-glucane |
Family Cites Families (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
JPS62129297A (ja) * | 1985-08-09 | 1987-06-11 | Toyo Jozo Co Ltd | カルシトニン遺伝子関連ペプチド誘導体 |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US4814567A (en) | 1987-07-08 | 1989-03-21 | Darko Jorge Lazaneo Dragicevic | Electro-thermic resonance system for heating liquid |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1990007936A1 (fr) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Therapies de recombinaison pour infections et troubles hyperproliferatifs |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
CA2489769A1 (fr) | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression des sequences polynocleotides exogenes chez un vertebre |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
EP0739904A1 (fr) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Réactifs bispécifiques pour le traitement du SIDA |
NZ234428A (en) | 1989-07-10 | 1997-08-22 | Amylin Corp | Use of an amylin antagonist in the treatment of obesity and essential hypertension |
JP4041535B2 (ja) | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ(ユーケー)リミテッド | 標的細胞にベクター構造体を運搬する組換レトロウィルス |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
EP0586505A1 (fr) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Anticorps d'heteroconjugues pour le traitement des infections a l'hiv |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
WO1992022653A1 (fr) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Procede de production d'anticorps humanises |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
CA2078539C (fr) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Procede de fabrication de chimere d'anticorps humain |
ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993010218A1 (fr) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs |
AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
DE4139664A1 (de) | 1991-12-02 | 1993-06-03 | Diagen Inst Molekularbio | Vorrichtung und verfahren zur isolierung und reinigung von nukleinsaeuren |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0650370A4 (fr) | 1992-06-08 | 1995-11-22 | Univ California | Procedes et compositions permettant de cibler des tissus specifiques. |
JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
EP0656064B1 (fr) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Immunoadhesines bispecifiques |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
CA2592997A1 (fr) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Vecteurs pseudo-adenoviraux |
DE4242396C2 (de) | 1992-12-09 | 1995-01-05 | Helopharm Petrik Co Kg | Aralkyldiaminderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1994021665A1 (fr) | 1993-03-24 | 1994-09-29 | Amylin Pharmaceuticals, Inc. | Recepteurs clones et methodes de criblage associees |
WO1994023697A1 (fr) | 1993-04-22 | 1994-10-27 | Depotech Corporation | Liposomes de cyclodextrine encapsulant des composes pharmacologiques et leurs procedes d'utilisation |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
GB9316989D0 (en) * | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
ATE437942T1 (de) | 1993-09-15 | 2009-08-15 | Novartis Vaccines & Diagnostic | Rekombinante alphavirus-vektoren |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
PT797676E (pt) | 1993-10-25 | 2006-05-31 | Canji Inc | Vector adenoviral recombinante e metodos de utilizacao |
BR9408072A (pt) | 1993-11-16 | 1997-08-12 | Depotech Corp | Vesículas com liberação controlada de ativos |
JPH07196700A (ja) | 1994-01-06 | 1995-08-01 | Sando Yakuhin Kk | 抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法 |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
WO1995030763A2 (fr) | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Vecteurs retroviraux a taux de recombinaison reduit |
WO1996005221A1 (fr) | 1994-08-16 | 1996-02-22 | Human Genome Sciences, Inc. | Recepteur de calcitonine |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
FR2732220B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue |
FR2732221B1 (fr) * | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
FR2732222B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux |
EP0737471A3 (fr) | 1995-04-10 | 2000-12-06 | L'oreal | Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue |
FR2732598B1 (fr) | 1995-04-10 | 1997-05-09 | Oreal | Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux |
EP0822830B1 (fr) * | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Anticorps anti-IL-8 dérivés de xenosouris immunisées |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
JPH11512396A (ja) * | 1995-09-05 | 1999-10-26 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
WO1997041223A1 (fr) | 1996-04-15 | 1997-11-06 | The University Of Miami | Clone moleculaire de proteine composante du recepteur du cgrp et son utilisation |
WO1997042338A1 (fr) | 1996-05-06 | 1997-11-13 | Chiron Corporation | Vecteurs retroviraux sans croisement |
US5746694A (en) | 1996-05-16 | 1998-05-05 | Wilk; Peter J. | Endoscope biopsy channel liner and associated method |
AU6596096A (en) | 1996-07-23 | 1998-02-10 | Smithkline Beecham Corporation | Calcitonin gene-related peptide receptor component factor (houdc44) |
US6586458B1 (en) * | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
JP3734315B2 (ja) | 1996-08-26 | 2006-01-11 | 株式会社小松製作所 | 曲げ加工方法および曲げ加工装置 |
WO1998009630A1 (fr) * | 1996-09-09 | 1998-03-12 | Smithkline Beecham Corporation | Composes et methodes |
WO1998011128A1 (fr) | 1996-09-10 | 1998-03-19 | Dr. Karl Thomae Gmbh | Aminoacides modifies, medicaments contenant ces composes et leur procede de production |
WO1998056779A1 (fr) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | 4-sulfinyle benzamides utiles comme antagonistes du recepteur de peptides lies au gene de la calcitonine |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
AU9692198A (en) | 1997-10-10 | 1999-05-03 | Kevin J. Donahue | Gene delivery compositions and methods |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
GB9809839D0 (en) * | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
JP2002525371A (ja) | 1998-09-30 | 2002-08-13 | メルク シャープ エンド ドーム リミテッド | Cgrpリガンドとしてのベンゾイミダゾリニルピペリジン |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1031350A1 (fr) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Utilisation d'un analogue de la gabapentine pour la fabrication d'un médicament pour la prevention et le traitement des douleurs viscérales |
US6313097B1 (en) * | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
CA2364484A1 (fr) | 1999-03-09 | 2000-09-14 | University Of Southern California | Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques |
US6521609B1 (en) | 1999-08-10 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
US20020162125A1 (en) † | 2001-03-06 | 2002-10-31 | Anne-Marie Salmon | Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal |
EP1438325B1 (fr) | 2001-09-27 | 2009-12-30 | Merck & Co., Inc. | Molecules d'adn isolees codant un recepteur humanise du peptide lie au gene de la calcitonine, animaux transgeniques non humains associes et methodes d'analyse |
US6767056B2 (en) | 2002-01-14 | 2004-07-27 | Shin Yeh Enterprise Co., Ltd. | Settee with a foldable tray-support unit |
US7026312B2 (en) | 2002-03-14 | 2006-04-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
ATE435239T1 (de) | 2002-03-29 | 2009-07-15 | Schering Corp | Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen |
AU2003239841A1 (en) | 2002-05-06 | 2003-11-17 | Grunenthal Gmbh | Cgrp binding nucleic acids |
US20040110170A1 (en) | 2002-05-18 | 2004-06-10 | The Regents Of The University Of California | Cloning and characterization of calcitonin gene related peptide receptors |
US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
ES2616539T3 (es) * | 2002-06-05 | 2017-06-13 | Bristol-Myers Squibb Company | Antagonistas de receptores de péptidos relacionados con el gen de calcitonina |
CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
MXPA05001649A (es) * | 2002-08-12 | 2005-05-27 | Birkir Sveinsson | Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis. |
DE10250082A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
WO2004050683A2 (fr) | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation |
PT1575517E (pt) | 2002-12-24 | 2012-05-28 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
DE602004013563D1 (de) * | 2003-03-14 | 2008-06-19 | Merck & Co Inc | Rantagonisten |
EP1606286B1 (fr) * | 2003-03-14 | 2011-05-11 | Merck Sharp & Dohme Corp. | Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp |
AU2004222378B2 (en) * | 2003-03-14 | 2008-08-14 | Merck Sharp & Dohme Corp. | Carboxamide spirohydantoin CGRP receptor antagonists |
WO2004083187A1 (fr) * | 2003-03-14 | 2004-09-30 | Merck & Co. Inc. | Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique |
ATE516803T1 (de) | 2003-03-14 | 2011-08-15 | Merck Sharp & Dohme | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
EP1615914B1 (fr) | 2003-04-15 | 2010-05-05 | Merck Sharp & Dohme Corp. | Antagonistes des recepteurs de cgrp |
WO2004097421A2 (fr) | 2003-04-29 | 2004-11-11 | Bayer Healthcare Ag | Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl) |
EP1646611A1 (fr) | 2003-07-15 | 2006-04-19 | Merck & Co., Inc. | Antagonistes des recepteurs cgrp de l'hydroxypyridine |
DE102004008261B3 (de) | 2004-02-20 | 2005-09-29 | Mtu Friedrichshafen Gmbh | Verfahren zur Steuerung und Regelung einer Brennkraftmaschinen-Generator-Einheit |
WO2005084672A1 (fr) | 2004-03-03 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Antagonistes de cgrp selectionnes, procedes de fabrication et utilisation en tant que medicament |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004018794A1 (de) * | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7279471B2 (en) * | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
JP2007533685A (ja) | 2004-04-20 | 2007-11-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 偏頭痛を治療するためのセロトニン再吸収阻害剤と組合わせたcgrpアンタゴニストの使用 |
DE102004027912A1 (de) | 2004-06-09 | 2005-12-29 | Grünenthal GmbH | Substituierte Cyclopenten-Verbindungen |
US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
TWI432196B (zh) | 2005-01-18 | 2014-04-01 | Euro Celtique Sa | 內臟痛的治療 |
EP1770091A1 (fr) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Antagonistes CGRP, leur procédé de préparation ansi que leur utilisation comme médicaments |
WO2007025212A2 (fr) | 2005-08-25 | 2007-03-01 | Wex Pharmaceuticals, Inc. | Utilisation de bloqueurs des canaux sodiques pour traiter les douleurs viscerales, ou les douleurs provoquees par un traitement anticancereux |
EP2056800B1 (fr) | 2005-08-26 | 2015-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methode d'administration de medicaments pour traitement de la douleur trigeminale |
EP1933714B1 (fr) | 2005-09-21 | 2020-03-18 | The Regents of The University of California | Systemes et compositions pour representer localement et traiter la douleur |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
ME00419B (fr) | 2005-11-14 | 2011-10-10 | Rinat Neuroscience Corp | Anticorps antagonistes orientes contre un peptide lie au gene de la calcitonine, et procedes d'utilisation correspondants |
AU2006316626A1 (en) | 2005-11-18 | 2007-05-31 | Merck Sharp & Dohme Corp. | Spirohydantoin aryl CGRP receptor antagonists |
WO2007076336A1 (fr) | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Traitement de la migraine avec des anticorps anti-cgrp |
US7834000B2 (en) | 2006-06-13 | 2010-11-16 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
AU2007275577A1 (en) | 2006-07-21 | 2008-01-24 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
AU2009220900B2 (en) | 2008-03-04 | 2014-09-11 | Teva Pharmaceuticals International Gmbh | Methods of treating chronic pain |
PL2265288T3 (pl) | 2008-03-04 | 2017-01-31 | Labrys Biologics Inc | Sposoby leczenia bólu zapalnego |
WO2010006168A2 (fr) | 2008-07-09 | 2010-01-14 | University Of Rochester | Procédés de traitement du cancer à l'aide d'un agent modulant l'activité du récepteur du peptide lié au gène de la calcitonine (« cgrp ») |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
IN2012DN02521A (fr) | 2009-08-28 | 2015-08-28 | Rinat Neuroscience Corp | |
AR081434A1 (es) | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
PT2710039T (pt) | 2011-05-20 | 2019-04-23 | Alderbio Holdings Llc | Composições anti-cgrp e a sua utilização |
NZ732970A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
EP2912643A1 (fr) | 2012-10-29 | 2015-09-02 | Net Entertainment NE AB | Architecture pour un jeu de casino en direct multi-joueurs, multi-jeux, multi-tables, multi-opérateurs&multi-juridictions |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
FI3119431T3 (fi) | 2014-03-21 | 2024-03-20 | Teva Pharmaceuticals Int Gmbh | Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi |
-
2006
- 2006-11-02 ME MEP-2008-623A patent/ME00419B/fr unknown
- 2006-11-02 KR KR1020087011418A patent/KR20080068062A/ko not_active Application Discontinuation
- 2006-11-02 PT PT68092071T patent/PT1957106E/pt unknown
- 2006-11-02 EP EP06809207.1A patent/EP1957106B2/fr active Active
- 2006-11-02 SI SI200632246T patent/SI2380592T1/en unknown
- 2006-11-02 HU HUE11166787A patent/HUE036940T2/hu unknown
- 2006-11-02 UA UAA200806484A patent/UA94244C2/ru unknown
- 2006-11-02 GE GEAP200610693A patent/GEP20115333B/en unknown
- 2006-11-02 EP EP16154418.4A patent/EP3045182B1/fr not_active Revoked
- 2006-11-02 PT PT161544184T patent/PT3045182T/pt unknown
- 2006-11-02 ES ES16154418.4T patent/ES2664854T3/es active Active
- 2006-11-02 PL PL16154418T patent/PL3045182T3/pl unknown
- 2006-11-02 CN CN2006800424430A patent/CN101309704B/zh active Active
- 2006-11-02 AU AU2006313434A patent/AU2006313434B2/en active Active
- 2006-11-02 JP JP2008540715A patent/JP5123197B2/ja active Active
- 2006-11-02 SI SI200632247T patent/SI3045182T1/en unknown
- 2006-11-02 ES ES11166787.9T patent/ES2664421T3/es active Active
- 2006-11-02 LT LTEP11166787.9T patent/LT2380592T/lt unknown
- 2006-11-02 PL PL06809207T patent/PL1957106T5/pl unknown
- 2006-11-02 RS RS20180536A patent/RS57192B1/sr unknown
- 2006-11-02 DK DK11166787.9T patent/DK2380592T3/en active
- 2006-11-02 EP EP20200867.8A patent/EP3842458A1/fr not_active Withdrawn
- 2006-11-02 PL PL11166787T patent/PL2380592T3/pl unknown
- 2006-11-02 KR KR1020117020735A patent/KR101250049B1/ko active Protection Beyond IP Right Term
- 2006-11-02 HU HUE16154418A patent/HUE036944T2/hu unknown
- 2006-11-02 ES ES06809207T patent/ES2433251T5/es active Active
- 2006-11-02 RS RSP-2008/0200A patent/RS20080200A/sr unknown
- 2006-11-02 CA CA2626120A patent/CA2626120C/fr active Active
- 2006-11-02 SI SI200631721T patent/SI1957106T2/sl unknown
- 2006-11-02 AP AP2008004467A patent/AP2008004467A0/xx unknown
- 2006-11-02 PT PT111667879T patent/PT2380592T/pt unknown
- 2006-11-02 EP EP16154411.9A patent/EP3069731A1/fr not_active Withdrawn
- 2006-11-02 US US12/093,638 patent/US8007794B2/en active Active
- 2006-11-02 EA EA200801094A patent/EA015526B1/ru active Protection Beyond IP Right Term
- 2006-11-02 DK DK16154418.4T patent/DK3045182T3/en active
- 2006-11-02 EP EP17152503.3A patent/EP3178493A1/fr not_active Withdrawn
- 2006-11-02 MY MYPI20081383A patent/MY153249A/en unknown
- 2006-11-02 NZ NZ568237A patent/NZ568237A/en unknown
- 2006-11-02 EP EP11166787.9A patent/EP2380592B1/fr active Active
- 2006-11-02 WO PCT/IB2006/003181 patent/WO2007054809A2/fr active Application Filing
- 2006-11-02 BR BRPI0618705A patent/BRPI0618705B8/pt active IP Right Grant
- 2006-11-02 DK DK06809207T patent/DK1957106T4/da active
- 2006-11-02 LT LTEP16154418.4T patent/LT3045182T/lt unknown
- 2006-11-02 CN CN201210315699.1A patent/CN103421114B/zh active Active
- 2006-11-02 RS RS20180545A patent/RS57194B1/sr unknown
-
2008
- 2008-04-15 IL IL190876A patent/IL190876A/en active Protection Beyond IP Right Term
- 2008-04-16 NO NO20081854A patent/NO344099B1/no active Protection Beyond IP Right Term
- 2008-04-21 ZA ZA200803484A patent/ZA200803484B/xx unknown
- 2008-05-13 TN TNP2008000213A patent/TNSN08213A1/fr unknown
- 2008-05-14 EC EC2008008451A patent/ECSP088451A/es unknown
- 2008-05-14 MA MA30924A patent/MA30136B1/fr unknown
- 2008-05-14 CR CR9975A patent/CR9975A/es unknown
- 2008-05-14 CU CU20080088A patent/CU23872B1/es active IP Right Grant
- 2008-05-14 SV SV2008002905A patent/SV2008002905A/es unknown
-
2009
- 2009-05-05 HK HK09104118.0A patent/HK1125837A1/xx unknown
-
2011
- 2011-07-11 US US13/179,846 patent/US8586045B2/en active Active
-
2012
- 2012-04-30 IL IL219503A patent/IL219503A0/en unknown
-
2013
- 2013-04-25 US US13/870,871 patent/US8597649B2/en active Active
- 2013-11-21 US US14/086,816 patent/US8734802B1/en active Active
-
2014
- 2014-04-14 US US14/251,925 patent/US9115194B2/en active Active
-
2015
- 2015-05-21 US US14/719,015 patent/US9328168B2/en active Active
- 2015-08-31 US US14/841,479 patent/US9340614B2/en active Active
- 2015-08-31 US US14/841,396 patent/US9266951B2/en active Active
- 2015-08-31 US US14/841,440 patent/US9346881B2/en active Active
-
2016
- 2016-02-16 US US15/044,552 patent/US9365648B1/en active Active
- 2016-05-05 US US15/147,265 patent/US20170081395A1/en not_active Abandoned
- 2016-09-25 IL IL248025A patent/IL248025A0/en unknown
- 2016-12-07 HK HK16113948A patent/HK1225627B/zh not_active IP Right Cessation
-
2017
- 2017-05-05 US US15/588,432 patent/US9890210B2/en active Active
- 2017-05-05 US US15/588,490 patent/US9884907B2/en active Active
- 2017-05-05 US US15/588,461 patent/US9890211B2/en active Active
- 2017-05-05 US US15/588,512 patent/US9884908B2/en active Active
-
2018
- 2018-01-30 US US15/883,218 patent/US10329343B2/en active Active
- 2018-04-18 US US15/956,580 patent/US20190092841A1/en not_active Abandoned
- 2018-05-14 HR HRP20180752TT patent/HRP20180752T1/hr unknown
- 2018-05-14 HR HRP20180753TT patent/HRP20180753T1/hr unknown
- 2018-05-21 CY CY20181100531T patent/CY1120249T1/el unknown
- 2018-05-24 CY CY20181100552T patent/CY1120267T1/el unknown
-
2019
- 2019-02-13 NO NO20190202A patent/NO344605B1/no unknown
- 2019-04-23 CY CY2019019C patent/CY2019019I1/el unknown
- 2019-05-08 LU LU00119C patent/LUC00119I2/fr unknown
- 2019-06-26 NL NL300997C patent/NL300997I2/nl unknown
- 2019-07-04 HU HUS1900035C patent/HUS1900035I1/hu unknown
- 2019-07-04 LU LU00126C patent/LUC00126I2/fr unknown
- 2019-07-17 LT LTPA2019015C patent/LTC2380592I2/lt unknown
- 2019-09-17 US US16/573,966 patent/US20200247878A1/en not_active Abandoned
- 2019-12-09 NO NO2019043C patent/NO2019043I1/no unknown
-
2021
- 2021-03-16 US US17/202,959 patent/US20220056114A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LUC00126I2 (fr) | ||
BRPI0601358B8 (pt) | Aplicador de clipe cirúrgico | |
BRPI0601402B8 (pt) | Aplicador de grampos cirúrgicos | |
JP2006001939A5 (fr) | ||
BR122017004709A2 (fr) | ||
JP2005187480A5 (fr) | ||
BRPI0609157A8 (fr) | ||
BRPI0608519A2 (fr) | ||
BR122020005056A2 (fr) | ||
BR122016029989A2 (fr) | ||
BRPI0604219A (fr) | ||
JP2006319164A5 (fr) | ||
JP2005316975A5 (fr) | ||
JP2007051398A5 (fr) | ||
BRPI0618215B8 (fr) | ||
BY2237U (fr) | ||
JP2007048050A5 (fr) | ||
FR2893480B3 (fr) | ||
CN105122969C (fr) | ||
CN300726695S (zh) | 调料瓶套装(a) | |
CN300726591S (zh) | 冷冰食品制作器 | |
CN300726005S (zh) | 鞋帮 | |
CN300726004S (zh) | 鞋帮 | |
CN300726003S (zh) | 鞋帮 | |
CN300726007S (zh) | 鞋底 |